Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours. Abstract #1251

Introduction: Despite advances, detection and quantification of NET activity by imaging remains a challenge.
Aim(s): We present the first in-man study of 18F-fluoroethyl triazole [Tyr3] octreotate (18F-FET-βAG TOCA) in NET patients to evaluate biodistribution, dosimetry and safety.
Materials and methods: 18F-FET-βAG TOCA was synthesized via the click reaction. Nine patients were enrolled into study. Eight patients with sporadic NET and 1 MEN1 syndrome. Mean age 56 yr (range 35-73 yr) and weight 75.2kg (91.2-66.3 kg).Patients underwent whole body PET-CT multi-bed scanning over 4h and venous blood samples were taken at specific intervals to measure 18F radioactivity concentration in blood and plasma. Regions of interest were drawn, to derive individual and mean organ residence times; effective dose (ED) was calculated with OLINDA 1.1
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Suraiya Dubash
Keywords: PET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Paola Mapelli
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#3022 Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms
Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Fabio Giannone
#2882 Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski
#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Mathias Loft